NASDAQ:OCAT Ocata Therapeutics (OCAT) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free OCAT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$8.47▼$8.4750-Day Range N/A52-Week Range$3.06▼$8.71VolumeN/AAverage Volume656,469 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ocata Therapeutics alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Ocata Therapeutics Stock (NASDAQ:OCAT)Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. OCAT Stock News HeadlinesMay 1, 2024 | finance.yahoo.comAstellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida dealMay 6, 2023 | marketwatch.comHuman Embryonic Stem Cells Market Latest Trends, Demand and Precise Outlook- Orthofix International N.V., Sumanas, Ocata TherapeuticsMay 3, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 3, 2023 | marketwatch.comTooth Regeneration Market Emerging Trends till 2031April 29, 2023 | marketwatch.comGlobal Tooth Regeneration Market by [2023-2029] with Revenue OutsourcingMarch 27, 2023 | marketwatch.comInduced Pluripotent Stem Cells Market by 2031March 8, 2023 | finance.yahoo.comCombined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlinMarch 6, 2023 | marketwatch.comTooth Regeneration Market is Booming Worldwide to Show Significant Growth over the Forecast 2023 to 2028May 3, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 25, 2023 | marketwatch.comTooth Regeneration Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028February 22, 2023 | marketwatch.comTooth Regeneration Market Booming With Rising Demands and Massive Opportunities, 2023 - 2028February 15, 2023 | marketwatch.comTooth Regeneration Market: What Strategies Do Companies to Increase Industry Share and Revenue Source?February 8, 2023 | marketwatch.comTooth Regeneration Market Size, Share, Top Region, Key Players, Application, Status and Forecast 2028January 11, 2023 | marketwatch.comTooth Regeneration Market 2023 : Future Trend, Business Strategies, Comprehensive Analysis and Forecast by 2028December 22, 2022 | marketwatch.comWith 3.8% CAGR, Tooth Regeneration Market 2023-2028 Find Out Essential Strategies To Expand The Business And Top Key Players | 88 Pages ReportDecember 10, 2022 | marketwatch.comTooth Regeneration Market Grows Massively, with Industry Entry Investment Feasibility, and Report Conclusion to 2028 | No. 92 Data InsightsNovember 24, 2022 | marketwatch.comEpithelial Stem Cells (Escs) Market Size 2022 Global Analysis Report by Share, Latest Trends, Market Dynamics and Forecast to 2026July 30, 2022 | marketwatch.comHuman Embryonic Stem Cells Market Share, Future Demand, Dynamics, Drivers, Research Methodology by 2026June 9, 2022 | investing.comBinh Duong Water Environment JSC (BWE)June 9, 2022 | investing.comTrias Sentosa Tbk (TRST)June 9, 2022 | investing.comHanyang Eng Co Ltd (045100)June 9, 2022 | investing.comIndo Acidatama Tbk (SRSN)April 13, 2022 | marketwatch.comTooth Regeneration Market Size 2022 Analysis by Competitive Landscape, Key Players, Growth Opportunities, Share and Forecast to 2024 Research ReportOctober 21, 2021 | investing.comOcata Therapeutics Inc (OCAT)September 1, 2021 | marketwatch.comHuman Embryonic Stem Cells Market Size, Future Trends, Industry Share, Growth Prospects, Key Players, Market Segments and Forecast 2021-2026See More Headlines Receive OCAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2015Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:OCAT Previous SymbolOTCMKTS:ACTC CUSIPN/A CIK1140098 Webwww.ocata.com Phone+1-508-7561212FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report OCAT Stock Analysis - Frequently Asked Questions How were Ocata Therapeutics' earnings last quarter? Ocata Therapeutics (NASDAQ:OCAT) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter. What other stocks do shareholders of Ocata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocata Therapeutics investors own include Antares Pharma (ATRS), Anavex Life Sciences (AVXL), Sarepta Therapeutics (SRPT), Prospect Capital (PSEC), Conatus Pharmaceuticals (CNAT), Geron (GERN), Athersys (ATHX), Cytori Therapeutics (CYTX), Microbot Medical (MBOT) and Nektar Therapeutics (NKTR). This page (NASDAQ:OCAT) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocata Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
